TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38239801

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker with Personal Activity Intelligence (PAI) on a mobile app
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Online training (additional access)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Online social support (additional access)
Number of subjects: 183
Study: 38240024

Group type: COMPARATOR
Intervention: Secukinumab 300 mg
Number of subjects: 24
Study: 38240199

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14420
Study: 38240201

Group type: EXPERIMENTAL
Intervention: Persistent severe disability trajectory
Number of subjects: 3533

Group type: EXPERIMENTAL
Intervention: Severe to moderate disability trajectory
Number of subjects: 3533

Group type: COMPARATOR
Intervention: No significant disability trajectory
Number of subjects: 3533
Study: 38240204

Group type: EXPERIMENTAL
Intervention: Low-dose edoxaban (15 mg once daily)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study: 38240222

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging (CMR)
Number of subjects: 102
Study: 38240379

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral vein puncture
Number of subjects: 254
Study: 38240504

Group type: EXPERIMENTAL
Intervention: AHUP-CPR
Number of subjects: 2232

Group type: COMPARATOR
Intervention: C-CPR
Number of subjects: 2232
Study: 38240536

Group type: EXPERIMENTAL
Intervention: Histamine-2 receptor antagonist (SUP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 38240773

Group type: EXPERIMENTAL
Intervention: RPO-enriched biscuits
Number of subjects: 651

Group type: COMPARATOR
Intervention: palm olein-enriched biscuits
Number of subjects: 651
Study: 38240778

Group type: EXPERIMENTAL
Intervention: GEN + VAN
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CAZ + VAN
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MOX
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: NT + VRC
Number of subjects: 93

Group type: COMPARATOR
Intervention: VRC
Number of subjects: 93

Group type: COMPARATOR
Intervention: NT
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: VRC + CAZ + VAN
Number of subjects: 93

Group type: COMPARATOR
Intervention: NT + CAZ + VAN
Number of subjects: 93
Study: 38240791

Group type: EXPERIMENTAL
Intervention: High-dose enoxaparin 30 mg q12hours (E30q12)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard-dose enoxaparin 40 mg q24hours (E40q24)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 Units q8hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 20
Study: 38240843

Group type: EXPERIMENTAL
Intervention: RBC transfusion (43.6% of patients)
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: Iron replacement (18.9% of patients)
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: ESA (10.1% of patients)
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: Vitamin B12 replacement (5.7% of patients)
Number of subjects: 1046

Group type: COMPARATOR
Intervention: No guideline-directed indication for transfusions (36.6% of 785 patients)
Number of subjects: 1046
Study: 38240875

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 185
Study: 38240916

Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel/docetaxel)
Number of subjects: 50
Study: 38240918

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI) tube with mechanical ventilation for four days or longer (n=57)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group: Patients extubated after three days or less of mechanical ventilation (n=43)
Number of subjects: 100
Study: 38241047

Group type: EXPERIMENTAL
Intervention: AKI alert combined with a care bundle
Number of subjects: 2208

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: AKI alert
Number of subjects: 2208
Study: 38241058

Group type: EXPERIMENTAL
Intervention: UFH (unfractionated heparin) median dose 8000 IU; clopidogrel 600 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ACT >196 s at 2 h
Number of subjects: 40
Study: 38241059

Group type: EXPERIMENTAL
Intervention: Estetrol (E4) 15 mg for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estetrol (E4) 2.5 mg for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38241070

Group type: EXPERIMENTAL
Intervention: Multiparametric RMT system with in-app components (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group using RADAR-base system without additional in-app components (n=50)
Number of subjects: 100
Study: 38241071

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients with depression and/or anxiety, assessed using the Chalder Fatigue Scale (CFQ-11) and the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients, assessed using the EQ-5D questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients, assessed using the 14-item Posttraumatic Stress Scale (PTSS-14)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 patients, examining the association between mental health symptoms and the severity of acute COVID-19
Number of subjects: 0
Study: 38241126

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38241163

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) in NIHSS score 9-12 group
Number of subjects: 1776

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) in NIHSS score 6-8 group
Number of subjects: 1776

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) in NIHSS score 13-16 group
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1776
Study: 38241166

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle-promoting practice implementation support from managers
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Support from managers to health care professionals
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Engagement of managers at all levels
Number of subjects: 42
Study: 38241247

Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (1 hour at 50% concentration) plus intravenous saline (100mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inhaled oxygen (1 hour at 50% concentration) plus intravenous midazolam (0.02 mg/kg in 100mL, up to 2mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inhaled oxygen plus intravenous midazolam
Number of subjects: 40
Study: 38241252

Group type: EXPERIMENTAL
Intervention: F64L genotype
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: I68L genotype
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: I107V genotype
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: S77Y genotype
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Mixed phenotype
Number of subjects: 141
Study: 38241265

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention for frailty reduction over 24 weeks
Number of subjects: 68
Study: 38241286

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38241321

Group type: EXPERIMENTAL
Intervention: 3D-RVT assessment before hepatectomy
Number of subjects: 3402

Group type: COMPARATOR
Intervention: 2D imaging assessment before hepatectomy
Number of subjects: 3402
Study: 38241354

Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT) for HCC
Number of subjects: 569
Study: 38241451

Group type: EXPERIMENTAL
Intervention: Education via videoconferencing at home (4 video conference sessions, educational booklets provided)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (face-to-face education)
Number of subjects: 60
Study: 38241489

Group type: EXPERIMENTAL
Intervention: Weight-loss attempts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight-related stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body image
Number of subjects: 0
Study: 38241600

Group type: EXPERIMENTAL
Intervention: 30 Gy chemoradiotherapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 70 Gy chemoradiotherapy
Number of subjects: 158
Study: 38241603

Group type: EXPERIMENTAL
Intervention: 70-gene risk score
Number of subjects: 5470

Group type: EXPERIMENTAL
Intervention: Low-risk 70-gene signature
Number of subjects: 5470

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy
Number of subjects: 5470

Group type: EXPERIMENTAL
Intervention: Tumor size and grade
Number of subjects: 5470
Study: 38241643

Group type: EXPERIMENTAL
Intervention: 480 mg letermovir once daily orally or intravenously (240 mg with cyclosporin A)
Number of subjects: 28
Study: 38241661

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins or methylprednisolone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 112
Study: 38241758

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38241785

Group type: EXPERIMENTAL
Intervention: Active SMS intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham SMS intervention
Number of subjects: 61
Study: 38242035

Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: High RDW (≥15%)
Number of subjects: 1244
Study: 38242195

Group type: EXPERIMENTAL
Intervention: PCV20 SC
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: PCV20 IM
Number of subjects: 668

Group type: COMPARATOR
Intervention: PCV13 SC
Number of subjects: 668
Study: 38242298

Group type: EXPERIMENTAL
Intervention: Machine learning model (random forest)
Number of subjects: 474
Study: 38242324

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (DAAs)
Number of subjects: 496
Study: 38242333

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy for Depression (BATD)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 234
Study: 38242351

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (n = 150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Attention and social contact control (n = 150)
Number of subjects: 300
Study: 38242358

Group type: EXPERIMENTAL
Intervention: Follow up program, patient education on PICS and pain, psychological intervention based on Rehm's self-control model.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow up program
Number of subjects: 0
Study: 38242530

Group type: EXPERIMENTAL
Intervention: Focal CF-sensing PFA catheter
Number of subjects: 10
Study: 38242550

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) at 90%-95% peak heart rate for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 38242575

Group type: EXPERIMENTAL
Intervention: Postoperative circulating tumour DNA (ctDNA) detection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative ctDNA positivity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Detectable postoperative ctDNA
Number of subjects: 50
Study: 38242717

Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg once daily plus pembrolizumab 200 mg every 3 weeks for 35 cycles
Number of subjects: 93
Study: 38242720

Group type: EXPERIMENTAL
Intervention: Immune-chemo (Ipilimumab and Nivolumab combined with anthracycline-based chemotherapy)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Chemo-only (anthracycline-based chemotherapy)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ipi/nivo-only (cross-over arm)
Number of subjects: 82
Study: 38242802

Group type: EXPERIMENTAL
Intervention: Intraoperative perfusion index
Number of subjects: 2534

Group type: EXPERIMENTAL
Intervention: Time-weighted average perfusion index
Number of subjects: 2534
Study: 38243011

Group type: EXPERIMENTAL
Intervention: ADNEX model with CA125
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: ADNEX model without CA125
Number of subjects: 894

Group type: COMPARATOR
Intervention: ROMA
Number of subjects: 894
Study: 38243094

Group type: EXPERIMENTAL
Intervention: Preoperative copeptin (> 14 pmol·L)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Postoperative copeptin measurements
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Revised cardiac risk index, body mass index, surgical risk, and preoperative hemoglobin
Number of subjects: 502
Study: 38243173

Group type: EXPERIMENTAL
Intervention: new powdered human milk fortifier (nHMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: commercially available human milk fortifiers (cHMF)
Number of subjects: 0
Study: 38243201

Group type: EXPERIMENTAL
Intervention: Action-like video game (Eco-Rescue) designed to improve attentional control abilities
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Casual puzzle video game (Bejeweled) acting as a positive distraction tool
Number of subjects: 150

Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 150
Study: 38243214

Group type: EXPERIMENTAL
Intervention: Combined intervention (brochures and brief training for oncologists)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 750
Study: 38243223

Group type: EXPERIMENTAL
Intervention: Truenat platform/MTB assays with rapid communication of results
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard of care (routine care including on-site sputum smear microscopy and referral to off-site Xpert testing)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Truenat platform/MTB assays
Number of subjects: 29
Study: 38243266

Group type: EXPERIMENTAL
Intervention: Continuous perioperative ketamine infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose ketamine in the postanesthesia care unit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38243272

Group type: EXPERIMENTAL
Intervention: Group A: PAI with 100 mg bupivacaine per knee (totaling 300 mg bupivacaine for ACB and PAI)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Group B: PAI with 50 mg bupivacaine per knee (totaling 200 mg bupivacaine for ACB and PAI)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ACB combined with 100 mg bupivacaine and PAI with another 100 mg bupivacaine
Number of subjects: 57

Group type: COMPARATOR
Intervention: ACB combined with 100 mg bupivacaine and PAI with 200 mg bupivacaine
Number of subjects: 57
Study: 38243291

Group type: EXPERIMENTAL
Intervention: Robotic-assisted bronchoscopy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Electromagnetic navigational bronchoscopy
Number of subjects: 400
Study: 38243296

Group type: EXPERIMENTAL
Intervention: Quabodepistat (QBS) in combination with delamanid and bedaquiline for 4 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard treatment (rifampicin, isoniazid, ethambutol, and pyrazinamide) for 6 months
Number of subjects: 120
Study: 38243297

Group type: EXPERIMENTAL
Intervention: Intestinal microbiota analysis using 16S metagenomics
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Linear discriminant analysis effect size (LEfSe)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Random forest (RF) methodology
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Intestinal microbiota analysis
Number of subjects: 1002
Study: 38243301

Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: SOC + 12 weeks of NRT
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: SOC + 6 weeks of SMS
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: SOC + NRT + SMS
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: All interventions (SOC, NRT, SMS)
Number of subjects: 800
Study: 38243307

Group type: EXPERIMENTAL
Intervention: Endorsement of buprenorphine misinformation
Number of subjects: 409
Study: 38243311

Group type: EXPERIMENTAL
Intervention: Broad-spectrum prophylaxis with vancomycin 1 g and gentamicin 5 mg/kg parenterally
Number of subjects: 414

Group type: COMPARATOR
Intervention: Standard prophylaxis with cefuroxime
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Broad-spectrum prophylaxis with vancomycin and gentamicin
Number of subjects: 414
Study: 38243396

Group type: EXPERIMENTAL
Intervention: Shear-wave elastography (SWE) at 30-degree knee flexion
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Shear-wave elastography (SWE) measurements
Number of subjects: 63
Study: 38243705

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4)
Number of subjects: 638
Study: 38243722

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 569
Study: 38243727

Group type: EXPERIMENTAL
Intervention: CVD IRT (integrated risk tool combining QRISK2 and polygenic risk score)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: CVD IRT
Number of subjects: 832
Study: 38243752

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (CT) - relugolix 40 mg, oestradiol 1 mg, norethisterone acetate 0.5 mg, once daily for up to 104 weeks.
Number of subjects: 802

Group type: COMPARATOR
Intervention: Placebo followed by relugolix CT (placebo for 24 weeks followed by relugolix CT).
Number of subjects: 802

Group type: COMPARATOR
Intervention: Delayed relugolix CT (relugolix 40 mg monotherapy for 12 weeks, followed by relugolix CT).
Number of subjects: 802
Study: 38243906

Group type: EXPERIMENTAL
Intervention: ANV419 administered by intravenous infusion at doses of 243 µg/kg (RP2D/MTD)
Number of subjects: 40
Study: 38243998

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary venous access
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard fluoroscopic technique for axillary venous access
Number of subjects: 270
Study: 38244105

Group type: EXPERIMENTAL
Intervention: Hypofractionated chemoradiation (40 Gy of 3D-conformal RT in 15 fractions over 3 weeks with concurrent weekly cisplatin 40 mg/m2)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard chemoradiation (45 Gy in 25 fractions over 5 weeks with concurrent weekly cisplatin 40 mg/m2)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Hypofractionated chemoradiation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard chemoradiation
Number of subjects: 59
Study: 38244145

Group type: EXPERIMENTAL
Intervention: After-hours robotic-assisted cholecystectomy (RAC)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Business-hours robotic-assisted cholecystectomy (RAC)
Number of subjects: 505
Study: 38244179

Group type: EXPERIMENTAL
Intervention: RYKINDO® (Rykindo) administered biweekly (Q2W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RISPERDAL® (Risperdal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RISPERDAL CONSTA® (Consta; Q2W)
Number of subjects: 0
Study: 38244384

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy-Taking it Further (MBCT-TiF)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Ongoing Mindfulness Practice (OMP)
Number of subjects: 164
Study: 38244557

Group type: EXPERIMENTAL
Intervention: Oral antimicrobial therapy
Number of subjects: 213

Group type: COMPARATOR
Intervention: Intravenous standard therapy
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Oral switch antimicrobial therapy
Number of subjects: 213
Study: 38244708

Group type: EXPERIMENTAL
Intervention: Multicomponent training (MCT) for 6 months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Multicomponent training (MCT) during detraining period
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 104
Study: 38244927

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) administered at 10 mg/kg intravenously on days 1 and 8 of 21-day cycles
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 113
Study: 38244989

Group type: EXPERIMENTAL
Intervention: Multivitamin-mineral (MVM) supplementation
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study: 38245015

Group type: EXPERIMENTAL
Intervention: Up-front ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard pharmacological therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard pharmacological therapy only
Number of subjects: 126
Study: 38245014

Group type: EXPERIMENTAL
Intervention: Self-directed exergaming intervention for upper limb rehabilitation for 3 months
Number of subjects: 0
Study: 38245113

Group type: EXPERIMENTAL
Intervention: Xpert MTB Host Response (Xpert HR) blood-based assay
Number of subjects: 1499
Study: 38245116

Group type: EXPERIMENTAL
Intervention: TAK-003
Number of subjects: 20099

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20099
Study: 38245324

Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation (SCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low frequency spinal cord stimulation (SCS)
Number of subjects: 0
Study: 38245375

Group type: EXPERIMENTAL
Intervention: NAVOY® Sepsis algorithm with active sepsis alerts
Number of subjects: 304

Group type: COMPARATOR
Intervention: Standard of care (silent predictions by NAVOY® Sepsis)
Number of subjects: 304
Study: 38245668

Group type: EXPERIMENTAL
Intervention: Influenza vaccination campaign offered free of cost to high-risk patients at one public tertiary-level hospital.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vaccination offered at the second public tertiary-level hospital.
Number of subjects: 0
Study: 38245724

Group type: EXPERIMENTAL
Intervention: Aspirin plus Ticagrelor for one month, followed by five months Ticagrelor monotherapy, and then Aspirin monotherapy for six months (Experimental group)
Number of subjects: 1908

Group type: COMPARATOR
Intervention: Aspirin plus Ticagrelor for 12 months (Reference group)
Number of subjects: 1908
Study: 38245730

Group type: EXPERIMENTAL
Intervention: Myoelectric interface for neurorehabilitation (MINT) conditioning
Number of subjects: 9
Study: 38245741

Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assist control ventilation (ACV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACV
Number of subjects: 0
Study: 38245818

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156